BACKGROUND: Use of multivitamin and mineral supplements is common among U.S. adults, yet few well-designed trials have assessed the reputed benefits. OBJECTIVE: To determine the effect of a daily multivitamin and mineral supplement on infection and well-being. DESIGN: Randomized, double-blind, placebo-controlled trial. SETTING:Primary care clinics at two medical centers in North Carolina. PARTICIPANTS: 130 community-dwelling adults stratified by age (45 to 64 years or >or=65 years) and presence of type 2 diabetes mellitus. INTERVENTION: Multivitamin and mineral supplement or placebo taken daily for 1 year. MEASUREMENTS: Incidence of participant-reported symptoms of infection, incidence of infection-associated absenteeism, and scores on the physical and mental health subscales of the Medical Outcomes Study 12-Item Short Form. RESULTS: More participants receiving placebo reported an infectious illness over the study year than did participants receiving multivitamin and mineral supplements (73% vs. 43%; P < 0.001). Infection-related absenteeism was also higher in the placebo group than in the treatment group (57% vs. 21%; P < 0.001). Participants with type 2 diabetes mellitus (n = 51) accounted for this finding. Among diabetic participants receivingplacebo, 93% reported an infection compared with 17% of those receiving supplements (P < 0.001). Medical Outcomes Study 12-Item Short Form scores did not differ between the treatment and placebo groups. CONCLUSIONS: A multivitamin and mineral supplement reduced the incidence of participant-reported infection and related absenteeism in a sample of participants with type 2 diabetes mellitus and a high prevalence of subclinical micronutrient deficiency. A larger clinical trial is needed to determine whether these findings can be replicated not only in diabetic persons but also in any population with a high rate of suboptimal nutrition or potential underlying disease impairment.
RCT Entities:
BACKGROUND: Use of multivitamin and mineral supplements is common among U.S. adults, yet few well-designed trials have assessed the reputed benefits. OBJECTIVE: To determine the effect of a daily multivitamin and mineral supplement on infection and well-being. DESIGN: Randomized, double-blind, placebo-controlled trial. SETTING: Primary care clinics at two medical centers in North Carolina. PARTICIPANTS: 130 community-dwelling adults stratified by age (45 to 64 years or >or=65 years) and presence of type 2 diabetes mellitus. INTERVENTION: Multivitamin and mineral supplement or placebo taken daily for 1 year. MEASUREMENTS: Incidence of participant-reported symptoms of infection, incidence of infection-associated absenteeism, and scores on the physical and mental health subscales of the Medical Outcomes Study 12-Item Short Form. RESULTS: More participants receiving placebo reported an infectious illness over the study year than did participants receiving multivitamin and mineral supplements (73% vs. 43%; P < 0.001). Infection-related absenteeism was also higher in the placebo group than in the treatment group (57% vs. 21%; P < 0.001). Participants with type 2 diabetes mellitus (n = 51) accounted for this finding. Among diabeticparticipants receiving placebo, 93% reported an infection compared with 17% of those receiving supplements (P < 0.001). Medical Outcomes Study 12-Item Short Form scores did not differ between the treatment and placebo groups. CONCLUSIONS: A multivitamin and mineral supplement reduced the incidence of participant-reported infection and related absenteeism in a sample of participants with type 2 diabetes mellitus and a high prevalence of subclinical micronutrient deficiency. A larger clinical trial is needed to determine whether these findings can be replicated not only in diabeticpersons but also in any population with a high rate of suboptimal nutrition or potential underlying disease impairment.
Authors: Howard H Moffet; Nancy Adler; Dean Schillinger; Ameena T Ahmed; Barbara Laraia; Joe V Selby; Romain Neugebauer; Jennifer Y Liu; Melissa M Parker; Margaret Warton; Andrew J Karter Journal: Int J Epidemiol Date: 2008-03-07 Impact factor: 7.196
Authors: Alison Avenell; Marion K Campbell; Jonathan A Cook; Philip C Hannaford; Mary M Kilonzo; Geraldine McNeill; Anne C Milne; Craig R Ramsay; D Gwyn Seymour; Audrey I Stephen; Luke D Vale Journal: BMJ Date: 2005-08-06
Authors: Ann F Walker; Georgios Marakis; Eleanor Simpson; Jessica L Hope; Paul A Robinson; Mohamed Hassanein; Hugh C R Simpson Journal: Br J Gen Pract Date: 2006-06 Impact factor: 5.386
Authors: Goran Bjelakovic; Dimitrinka Nikolova; Lise Lotte Gluud; Rosa G Simonetti; Christian Gluud Journal: Cochrane Database Syst Rev Date: 2012-03-14
Authors: J Steven A Simpson; Susan G Crawford; Estelle T Goldstein; Catherine Field; Ellen Burgess; Bonnie J Kaplan Journal: BMC Psychiatry Date: 2011-04-18 Impact factor: 3.630